LTZ-232

LTZ-232 is a bispecific antibody (myeloid cell engager) from LTZ Therapeutics. A first-in-class bispecific myeloid engager targeting EpCAM, built on the company's Universal Myeloid Cell Engager (U-MCE) platform. Its furthest stage is phase 1, for metastatic colorectal cancer, other advanced solid tumours and malignant ascites. ClinicalTrials.gov registers it in one study linked below. FDA IND cleared July 2026; first participant dosed in phase 1/1b, announced 29 October 2026 (NCT07878988). Whether it works in people has not been established unless a trial below reports it.